Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CACNA1I | Q9P0X4 | 9/20 | 0.46 |
| ▸ | KCNH2 | Q12809 | 6/20 | 0.46 |
| ▸ | GNAO1 | P09471 | 2/20 | 0.35 |
| ▸ | GNAI3 | P08754 | 1/20 | 0.35 |
| ▸ | GNAI1 | P63096 | 1/20 | 0.35 |
| ▸ | EPHX1 | P07099 | 2/20 | 0.35 |
| ▸ | EPHX2 | P34913 | 2/20 | 0.35 |
| ▸ | CARM1 | Q86X55 | 1/20 | 0.33 |
| ▸ | PRMT6 | Q96LA8 | 1/20 | 0.33 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.33 |
| ▸ | DPP4 | P27487 | 1/20 | 0.32 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.32 |
| ▸ | OPRL1 | P41146 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23919190 | 0.85 | CACNA1I (0.49) | CACNA1IKCNH2GNAO1GNAI3GNAI1 | |
| SCHEMBL19248417 | 0.80 | CACNA1I (0.51) | CACNA1IKCNH2GNAO1GNAI3GNAI1 | |
| SCHEMBL17307155 | 0.77 | CACNA1I (0.43) | CACNA1IKCNH2GNAO1DPP4OPRM1 | |
| SCHEMBL24060970 | 0.75 | GNAO1 (0.47) | CACNA1IKCNH2GNAO1DPP4 | |
| SCHEMBL23919061 | 0.75 | CACNA1I (0.44) | CACNA1IKCNH2GNAO1DPP4OPRM1 | |
| SCHEMBL19258139 | 0.75 | CACNA1I (0.54) | CACNA1IKCNH2 | |
| SCHEMBL13101574 | 0.72 | CACNA1I (0.46) | CACNA1IKCNH2GNAO1DPP4OPRM1 | |
| SCHEMBL22166533 | 0.71 | CACNA1I (0.40) | CACNA1IKCNH2GNAO1DPP4 | |
| SCHEMBL13965735 | 0.70 | CACNA1I (0.42) | CACNA1IKCNH2GNAO1GNAI3GNAI1 | |
| SCHEMBL21235240 | 0.70 | CACNA1I (0.39) | CACNA1IKCNH2GNAO1CARM1PRMT6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10227332-B2 | T-type calcium channel modulator and uses thereof | UTI LIMITED PARTNERSHIP (CA) | 2019-03-12 | — | — | US | disclosed |
| US-20170233374-A1 | T-TYPE CALCIUM CHANNEL MODULATOR AND USES THEREOF | UTI LIMITED PARTNERSHIP (CA) | 2017-08-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10227332-B2 | T-type calcium channel modulator and uses thereof | CACNA1E, CACNA1G, TRPC6 | CACNA1I 7/4885KCNH2 76/4885GNAO1 529/4885 |
| US-20170233374-A1 | T-TYPE CALCIUM CHANNEL MODULATOR AND USES THEREOF | CACNA1E, CACNA1G, TRPC6 | CACNA1I 8/4885KCNH2 75/4885GNAO1 594/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.